National program scale-up and patient outcomes in a pediatric antiretroviral treatment program, Thailand, 2000-2007

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 4, 2010, Pages 423-429

  McConnell, Michelle S ^a,b   Chasombat, Sanchai ^a   Siangphoe, Umaporn ^a   Yuktanont, Porntip ^a   Lolekha, Rangsima ^a   Pattarapayoon, Naparat ^a   Kohreanudom, Surapol ^a   Mock, Philip A ^a   Fox, Kimberley ^a,b   Thanprasertsuk, Sombat ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN;

ARTICLE; CHILD; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; SCALE UP; THAILAND; TREATMENT OUTCOME; BLOOD; BODY WEIGHT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INFANT; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PUBLIC HEALTH; UTILIZATION REVIEW;

ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE; THAILAND; TREATMENT OUTCOME;

EID: 77955501817     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181dc5eb0     Document Type: Article

References (43)

1. World Health Organization. AIDS epidemic update. 2007. Available at: http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed January 8, 2009.
2. de Martino M, Tovo P, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190-197.
3. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
4. McConnell M, Byers R, Frederick T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr. 2005;38:488-494.
5. Ciaranello A, Chang Y, Marguilis A, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49:1915-1927.
6. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapy among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18: 1905-1913.
7. George E, Noel F, Bois G, et al. Antiretroviral therapy for HIV-infected children in Haiti. J Infect Dis. 2007;195:1411-1418.
8. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-1 positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134-e1140.
9. Kamya M, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193.
10. O'Brien D, Sauvageot D, Zachariah R, et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955-1960.
11. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis. 2005;41: 100-107.
12. Puthanakit T, Aurpibul L, Oberdorfer A, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007;26:953-956.
13. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virological response of African HIV-1 infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319.
14. Sutcliffe C, van Dijk J, Bolton-Moore C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet. 2008;8:477-489.
15. The Kids ART LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in sub-saharan Africa. J Acquir Immune Defic Syndr. 2008;49:523-531.
16. Bolton-Moore C, Mubiana-Mbewe M, Cantrell R, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
17. European Collaborative Study. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis. 2006;193:954-962.
18. Resino S, Alvaro-Meca A, De Jose I, et al. Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency. Pediatr Infect Dis J. 2006;25:365-368.
19. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42:862-869.
20. UNAIDS. Report on the global AIDS epidemic 2008. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008- Global-report.asp. Accessed September 9 2009.
21. Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, et al. The national access to antiretroviral program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health. 2006;37:704-715.
22. Chasombat S, McConnell MS, Sianphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009;50:506-512
23. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):961-962.
24. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009. Available at: http://aidsinfo.nih. gov/contentfiles/PediatricGuidelines.pdf. Accessed February 18, 2010.
25. Chokephaibulkit K, Plipat N, Cressey T, et al. Pharmokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS. 2005;19: 1495-1499.
26. Borghi E, de Onis M, Garza C. Construction of the World Health Organization child growth standards: selection of methods for attained growth curves. Stat Med. 2006;25:247-265.
27. Diggle PJ, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. 2nd ed. New York, NY: Oxford Univerity Press; 2002.
28. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia. JAMA. 2006;296:782-793.
29. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
30. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599-604.
31. Hansudewechakul R, Naiwatanakul T, Faikratok W, et al. Clinical outcomes in a community-based pediatric HIV care network in Chiang Rai, Thailand, 2002-2008. Presented at: 5th IAS conference on HIV pathogenesis, treatment and prevention; July 19-22, 2009; Capetown, South Africa.
32. De Baets A, Bulterys M, Abrams E, et al. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. Pediatr Infect Dis J. 2007;26:163-173.
33. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study. Lancet. 2004;363:1253-1263.
34. Puthanakit T, Kerr S, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009;28:488-492.
35. World Health Organization. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting. 2008. Available at: http://www.who.int/hiv/pub/meetingreports/art-meeting- april2008/en/index.html. Accessed September 9, 2009.
36. Nikolic-Djokic D, Essajee S, Rigaud M, et al. Immunoreconstitution in children receiving highly active antiretroviral therapy depend on the CD4 cell percentage at baseline. J Infect Dis. 2002;185:290-298.
37. O'Brien D, Sauvageot D, Olson D, et al. Treatment outcomes stratified by baseline immunological status among young children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007;44:1245-1248.
38. Jittamala P, Puthanakit T, Chaiinseeard S, et al. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretro-viral therapy. Pediatr Infect Dis J. 2009;28:826-830.
39. Sohn A, Ananworanich J. HAART for children with treatment failure. HIV Ther. 2009;3:485-495.
40. Phillips A, Pillay D, Miners A, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 count, or clinical observation alone; a computer simulation model. Lancet. 2008;371:1443-1451.
41. Badri M, Lawn S, Wood R. Utility of CD4 counts for early prediction of virologic failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8:89.
42. Akarasewi P, Punsuwan N, Naiwatanakul T, et al. A case-based surveillance system to monitor HIV-exposed infant outcomes in Thailand, 2001-2007. Presented at: Global HIV Surveillance Meeting; March 2-5, 2009; Bangkok, Thailand.
43. Bureau of Epidemiology Department of Disease Control, Thailand MOPH, Bureau of Health Promotion, Thailand MOPH. Report on the PMTCT national program evaluation meeting; February 2 2009; Bangkok, Thailand.